MET and cancer: Signaling transduction by HGF and mesenchymal–epithelial transition tyrosine kinase receptor (MET) is aberrantly activated in many types of cancers, and experimental evidence suggests that the activation of the HGF/MET pathway facilitates cancer cell proliferation, therapy resistance, metastasis, and adaptive response to adverse microenvironments (3–5).